Incannex Healthcare Inc. has been recognized with the Research and Development Award in the Respiratory Disorders category at the 2025 Clinical Trials Arena Excellence Awards for its work on IHL-42X, an oral fixed-dose combination therapy aimed at treating obstructive sleep apnea (OSA). The award highlights Incannex’s research-driven approach and the significance of developing innovative, evidence-based alternatives to device-based OSA therapies. The company’s IHL-42X program is advancing into late-stage development, with a focus on addressing unmet medical needs for patients struggling with current treatment options. The recognition reflects the industry-wide relevance of Incannex’s ongoing research in respiratory medicine. The announcement pertains to the award and does not specify the presentation of detailed scientific research results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-004488), on January 15, 2026, and is solely responsible for the information contained therein.